219 related articles for article (PubMed ID: 37543290)
1. Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
Kelvin JM; Chimenti ML; Zhang DY; Williams EK; Moore SG; Humber GM; Baxter TA; Birnbaum LA; Qui M; Zecca H; Thapa A; Jain J; Jui NT; Wang X; Fu H; Du Y; Kemp ML; Lam WA; Graham DK; DeRyckere D; Dreaden EC
J Control Release; 2023 Sep; 361():470-482. PubMed ID: 37543290
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.
Summers RJ; Jain J; Vasileiadi E; Smith B; Chimenti ML; Yeung TY; Kelvin J; Wang X; Frye SV; Earp HS; Tyner JW; Dreaden EC; DeRyckere D; Graham DK
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551626
[TBL] [Abstract][Full Text] [Related]
3. Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.
Kelvin JM; Jain J; Thapa A; Qui M; Birnbaum LA; Moore SG; Zecca H; Summers RJ; Switchenko JM; Costanza E; Uricoli B; Wang X; Jui NT; Fu H; Du Y; DeRyckere D; Graham DK; Dreaden EC
Pharm Res; 2023 Sep; 40(9):2133-2146. PubMed ID: 37704893
[TBL] [Abstract][Full Text] [Related]
4. Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML.
Kelvin JM; Jain J; Thapa A; Qui M; Birnbaum LA; Moore SG; Zecca H; Summers RJ; Costanza E; Uricoli B; Wang X; Jui NT; Fu H; Du Y; DeRyckere D; Graham DK; Dreaden EC
bioRxiv; 2023 Mar; ():. PubMed ID: 36993676
[TBL] [Abstract][Full Text] [Related]
5. Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
Goto H; Yoshino Y; Ito M; Nagai J; Kumamoto T; Inukai T; Sakurai Y; Miyagawa N; Keino D; Yokosuka T; Iwasaki F; Hamanoue S; Shiomi M; Goto S
Cancer Chemother Pharmacol; 2020 Apr; 85(4):773-783. PubMed ID: 32144432
[TBL] [Abstract][Full Text] [Related]
6. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
O'Brien S; Schiller G; Lister J; Damon L; Goldberg S; Aulitzky W; Ben-Yehuda D; Stock W; Coutre S; Douer D; Heffner LT; Larson M; Seiter K; Smith S; Assouline S; Kuriakose P; Maness L; Nagler A; Rowe J; Schaich M; Shpilberg O; Yee K; Schmieder G; Silverman JA; Thomas D; Deitcher SR; Kantarjian H
J Clin Oncol; 2013 Feb; 31(6):676-83. PubMed ID: 23169518
[TBL] [Abstract][Full Text] [Related]
7. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
[TBL] [Abstract][Full Text] [Related]
8. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
10. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
12. Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia.
Crazzolara R; Cisterne A; Thien M; Hewson J; Baraz R; Bradstock KF; Bendall LJ
Blood; 2009 Apr; 113(14):3297-306. PubMed ID: 19196656
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
14. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
15. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
Patte C; Auperin A; Michon J; Behrendt H; Leverger G; Frappaz D; Lutz P; Coze C; Perel Y; Raphaël M; Terrier-Lacombe MJ;
Blood; 2001 Jun; 97(11):3370-9. PubMed ID: 11369626
[TBL] [Abstract][Full Text] [Related]
16. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
17. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP
Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015
[TBL] [Abstract][Full Text] [Related]
18. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB
Blood Cancer J; 2014 Aug; 4(8):e232. PubMed ID: 25083816
[TBL] [Abstract][Full Text] [Related]
19. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
[TBL] [Abstract][Full Text] [Related]
20. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
Kantarjian H; Ravandi F; Short NJ; Huang X; Jain N; Sasaki K; Daver N; Pemmaraju N; Khoury JD; Jorgensen J; Alvarado Y; Konopleva M; Garcia-Manero G; Kadia T; Yilmaz M; Bortakhur G; Burger J; Kornblau S; Wierda W; DiNardo C; Ferrajoli A; Jacob J; Garris R; O'Brien S; Jabbour E
Lancet Oncol; 2018 Feb; 19(2):240-248. PubMed ID: 29352703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
